PL3292135T3 - Zastosowanie polipeptydu do wpływania na sygnalizację odpornościową i/lub wpływania na funkcję bariery jelitowej i/lub modulowania stanu metabolicznego - Google Patents

Zastosowanie polipeptydu do wpływania na sygnalizację odpornościową i/lub wpływania na funkcję bariery jelitowej i/lub modulowania stanu metabolicznego

Info

Publication number
PL3292135T3
PL3292135T3 PL16724321.1T PL16724321T PL3292135T3 PL 3292135 T3 PL3292135 T3 PL 3292135T3 PL 16724321 T PL16724321 T PL 16724321T PL 3292135 T3 PL3292135 T3 PL 3292135T3
Authority
PL
Poland
Prior art keywords
polypeptide
barrier function
intestinal barrier
metabolic status
immune signalling
Prior art date
Application number
PL16724321.1T
Other languages
English (en)
Polish (pl)
Inventor
Clara BELZER
Willem Meindert De Vos
Patrice Daniel Cani
Original Assignee
Wageningen Universiteit
Université Catholique de Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wageningen Universiteit, Université Catholique de Louvain filed Critical Wageningen Universiteit
Publication of PL3292135T3 publication Critical patent/PL3292135T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL16724321.1T 2015-05-06 2016-05-04 Zastosowanie polipeptydu do wpływania na sygnalizację odpornościową i/lub wpływania na funkcję bariery jelitowej i/lub modulowania stanu metabolicznego PL3292135T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15166598 2015-05-06
PCT/EP2016/060033 WO2016177797A1 (en) 2015-05-06 2016-05-04 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status

Publications (1)

Publication Number Publication Date
PL3292135T3 true PL3292135T3 (pl) 2023-01-02

Family

ID=74184294

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16724321.1T PL3292135T3 (pl) 2015-05-06 2016-05-04 Zastosowanie polipeptydu do wpływania na sygnalizację odpornościową i/lub wpływania na funkcję bariery jelitowej i/lub modulowania stanu metabolicznego

Country Status (14)

Country Link
US (2) US10738089B2 (enExample)
EP (1) EP3292135B1 (enExample)
JP (1) JP6894382B2 (enExample)
KR (1) KR102736980B1 (enExample)
CN (1) CN107980043B (enExample)
AU (2) AU2016257315A1 (enExample)
DK (1) DK3292135T3 (enExample)
EA (1) EA201700507A1 (enExample)
ES (1) ES2934138T3 (enExample)
HK (1) HK1252412A1 (enExample)
IL (1) IL255405B (enExample)
MX (1) MX390092B (enExample)
PL (1) PL3292135T3 (enExample)
WO (1) WO2016177797A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
EP3292135B1 (en) 2015-05-06 2022-09-21 Wageningen Universiteit Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
DK3347030T3 (da) * 2015-09-10 2021-08-09 Univ Catholique Louvain Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
WO2018165338A2 (en) * 2017-03-07 2018-09-13 uBiome, Inc. Therapeutic & diagnostics compositions targeting toll-like receptors and methods thereof
WO2019018410A1 (en) * 2017-07-17 2019-01-24 The General Hospital Corporation COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
CN113164526A (zh) 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
WO2020076043A1 (ko) * 2018-10-08 2020-04-16 한국생명공학연구원 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도
KR102197180B1 (ko) 2018-10-11 2020-12-31 주식회사 고바이오랩 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물
CN110079474B (zh) * 2019-04-12 2022-11-25 沈阳药科大学 一种高密度培养艾克曼嗜黏蛋白菌的方法
KR102263030B1 (ko) * 2019-05-07 2021-06-10 한국생명공학연구원 염증성 장질환의 예방 또는 치료용 펩타이드
CN110227085A (zh) * 2019-07-16 2019-09-13 江苏省中医院 Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用
US20240226186A9 (en) * 2019-09-25 2024-07-11 Healthbiome Obligate anaerobic human intestinal microbe for cancer treatment, and use thereof
KR102397916B1 (ko) * 2019-10-01 2022-05-17 (주)헬스바이옴 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
CN110950937B (zh) * 2019-11-25 2021-05-04 安徽大学 一种改造的艾克曼菌Amuc_1100蛋白及其制备方法和应用
WO2021139766A1 (en) * 2020-01-10 2021-07-15 Huang Chih Hung Peptide interacting with toll-like receptor 2 and the composition comprising the same
WO2021194281A1 (ko) 2020-03-25 2021-09-30 한국생명공학연구원 아커만시아 뮤시니필라 유래의 tars 또는 이의 단편 및 이의 용도
US20210322492A1 (en) * 2020-04-16 2021-10-21 Amucin Oy Ltd Probiotic strains and uses thereof
CN111690044B (zh) * 2020-05-06 2022-03-01 中南大学湘雅二医院 Amuc1100蛋白的用途
WO2022002660A1 (en) 2020-07-01 2022-01-06 Wageningen Universiteit Amuc-1100 polypeptide variants for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
WO2022098051A1 (ko) * 2020-11-05 2022-05-12 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드
CN113413466B (zh) * 2020-12-15 2022-08-19 和度生物医药(上海)有限公司 用于治疗癌症的amuc_1100和免疫检查点调节剂的组合疗法
CN115364198A (zh) * 2022-08-23 2022-11-22 广州康泽医疗科技有限公司 膜蛋白Amuc_1100在促进前脂肪细胞脂解和棕色化中的应用
CN116059254B (zh) * 2023-02-27 2025-04-18 广州知易生物科技有限公司 嗜黏蛋白阿克曼氏菌在制备用于改善和治疗多发性硬化症药物中的应用
KR102835266B1 (ko) 2023-09-11 2025-07-17 충남대학교산학협력단 아커만시아 뮤시니필라 m3-2 균주 및 이의 용도
CN117304264B (zh) * 2023-11-27 2024-02-06 中国科学院烟台海岸带研究所 一种具有肠屏障保护功能的五肽rp5及其应用
CN118063567B (zh) * 2024-03-03 2025-11-21 吉林大学 一种用于炎性肠病治疗的重组蛋白的制备与应用
CN119874827B (zh) * 2025-03-27 2025-06-13 杭州康源食品科技有限公司 一种具有免疫调节作用的九肽及其制备和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
DE60229508D1 (de) * 2001-02-28 2008-12-04 Nat Inst Of Advanced Ind Scien Drosophila-stamm, der in diesen übertragene(s) bradeion-gen(e) enthält
AU2003296330A1 (en) * 2002-12-10 2004-06-30 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
US20050180962A1 (en) 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
WO2005030133A2 (en) * 2003-09-22 2005-04-07 Yale University Treatment with agonists of toll-like receptors
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US7812121B2 (en) 2006-08-31 2010-10-12 Baker Audrey E GLP-2 mimetibodies, polypeptides, compositions, methods and uses
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
FR2944524B1 (fr) 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
US8784798B2 (en) 2009-05-11 2014-07-22 Nestec S.A. Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders
WO2011137369A1 (en) * 2010-04-29 2011-11-03 The Regents Of The University Of California Production of gamma-aminobutyric acid by recombinant microorganisms
US9104670B2 (en) 2010-07-21 2015-08-11 Apple Inc. Customized search or acquisition of digital media assets
CN103154670B (zh) 2010-10-20 2016-02-24 皇家飞利浦电子股份有限公司 用于识别电气网络中的耗电器的分解装置和分解方法
ES2565407T3 (es) 2010-11-05 2016-04-04 Nestec S.A. Procedimiento para la preparación de un producto alimenticio para animales de compañía, el cual contiene microorganismos probióticos
EP2449891A1 (en) 2010-11-05 2012-05-09 Nestec S.A. Drinking yoghurt preparations containing non-replicating probiotic micro-organisms
IN2014DN07752A (enExample) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
KR101740893B1 (ko) * 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
EP3292135B1 (en) 2015-05-06 2022-09-21 Wageningen Universiteit Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
DK3347030T3 (da) 2015-09-10 2021-08-09 Univ Catholique Louvain Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
US11071626B2 (en) 2018-03-16 2021-07-27 W. L. Gore & Associates, Inc. Diametric expansion features for prosthetic valves

Also Published As

Publication number Publication date
CN107980043A (zh) 2018-05-01
WO2016177797A1 (en) 2016-11-10
ES2934138T3 (es) 2023-02-17
IL255405B (en) 2022-01-01
DK3292135T3 (da) 2022-10-31
US20210147489A1 (en) 2021-05-20
EA201700507A1 (ru) 2018-05-31
CN107980043B (zh) 2021-09-24
HK1252412A1 (zh) 2019-05-24
US11466057B2 (en) 2022-10-11
EP3292135A1 (en) 2018-03-14
US10738089B2 (en) 2020-08-11
KR102736980B1 (ko) 2024-12-02
AU2016257315A1 (en) 2017-11-23
AU2020267210A1 (en) 2020-12-17
MX390092B (es) 2025-03-11
KR20180011130A (ko) 2018-01-31
IL255405A0 (en) 2017-12-31
JP2018515502A (ja) 2018-06-14
CA2984985A1 (en) 2016-11-10
AU2020267210B2 (en) 2023-10-12
JP6894382B2 (ja) 2021-06-30
NZ737765A (en) 2024-08-30
MX2017014111A (es) 2018-02-26
EP3292135B1 (en) 2022-09-21
BR112017023751A2 (pt) 2018-07-31
US20180265554A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
IL255405B (en) Use of a polypeptide to induce an immune signal and/or to influence the activity of the intestinal barrier and/or to regulate a metabolic state
PT3292135T (pt) Uso de um polipéptido para efetuar a sinalização imunitária e/ou afetar a função de barreira intestinal e/ou regular o estado metabólico
IL252812B (en) Pyrin polypeptide and immune modulation
GB2566753B (en) Full face respirator
HUE068462T2 (hu) Dobozfedél
AU363846S (en) Closure
IL250571B (en) coupling and gasket
GB2561542B (en) Ampoule closure
SG11202001400YA (en) Closure
ZA201704991B (en) Container closure systems
IL247551B (en) A peptide drug in the form of a dry powder
ZA201905760B (en) Tamper evident closure
ZA201800643B (en) Closure system
AU363132S (en) Closure
PL3679987T3 (pl) Przegroda ognioodporna
GB201614915D0 (en) Closure
AP00995S1 (en) Security seal
PH32018000900S1 (en) Security seal
GB201708099D0 (en) Closure
AU201711445S (en) Closure
GB2537810B (en) Flexible seal
GB201522995D0 (en) A closure system
PL3163132T3 (pl) Urządzenie do uszczelniania oraz system do nakładania zawierający takie urządzenie
GB201506785D0 (en) Face mask and face seal component
GB201504273D0 (en) Overhood seal and use thereof